S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

iTeos Therapeutics Insider Trades

+0.01 (+0.05%)
(As of 05/13/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
650,800 shs
Average Volume
529,757 shs
Market Capitalization
$659.87 million
P/E Ratio
Dividend Yield

iTeos Therapeutics (NASDAQ:ITOS) Insider Buying and Selling Activity

Insider Ownership
Number Of
Insiders Buying
(Last 12 Months)
Amount Of
Insider Buying
(Last 12 Months)
$1.10 M
Number Of
Insiders Selling
(Last 12 Months)
Amount Of
Insider Selling
(Last 12 Months)
$71.02 M

Insider Buying and Selling by Quarter

Get ITOS Insider Trade Alerts

Want to know when executives and insiders are buying or selling iTeos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

iTeos Therapeutics (NASDAQ:ITOS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2022Aaron I DavisDirectorSell338,000$18.25$6,168,500.002,154,058  
5/9/2022Aaron I DavisDirectorSell225,000$23.40$5,265,000.002,592,058  
5/2/2022Aaron I DavisDirectorSell100,000$27.49$2,749,000.002,817,058  
4/28/2022Aaron I DavisDirectorSell150,000$27.40$4,110,000.003,042,058  
4/18/2022Michel DetheuxCEOSell11,500$31.87$366,505.0026,263  
3/22/2022Aaron I DavisDirectorBuy30,000$32.28$968,400.00  
3/22/2022Michel DetheuxCEOSell18,437$34.17$629,992.29  
3/17/2022Boxer Capital, LlcMajor ShareholderSell575,201$35.25$20,275,835.25  
3/11/2022Joanne Jenkins LagerInsiderSell3,500$36.01$126,035.00  
3/1/2022Yvonne McgrathInsiderSell10,000$36.76$367,600.00  
2/23/2022Michel DetheuxCEOSell14,500$34.34$497,930.00  
2/11/2022Joanne Jenkins LagerInsiderSell3,500$35.85$125,475.00  
1/25/2022Michel DetheuxCEOSell14,500$35.68$517,360.00  
1/14/2022Joanne Jenkins LagerInsiderSell3,500$39.32$137,620.00  
1/4/2022Bioventures 2018 L.P. MpmMajor ShareholderSell128,550$42.66$5,483,943.00  
1/3/2022Detlev BiniszkiewiczDirectorSell3,500$51.90$181,650.00  
1/3/2022Joanne Jenkins LagerInsiderSell7,000$51.90$363,300.00  
12/27/2021Matthew GallCFOSell5,000$46.45$232,250.00  
12/22/2021Michel DetheuxCEOSell16,163$45.03$727,819.89  
12/20/2021David HallalDirectorSell50,000$43.57$2,178,500.00  
12/20/2021Michel DetheuxCEOSell9,111$43.94$400,337.34  
12/17/2021Joanne Jenkins LagerInsiderSell7,000$41.00$287,000.00  
12/10/2021Joanne Jenkins LagerInsiderSell3,500$34.50$120,750.00  
12/6/2021Bioventures 2018 L.P. MpmMajor ShareholderSell10,208$32.59$332,678.72  
12/3/2021Bioventures 2018 L.P. MpmMajor ShareholderSell20,167$34.79$701,609.93  
12/1/2021Bioventures 2018 L.P. MpmMajor ShareholderSell12,395$34.28$424,900.60  
11/29/2021Bioventures 2018 L.P. MpmMajor ShareholderSell10,371$34.49$357,695.79  
11/26/2021Bioventures 2018 L.P. MpmMajor ShareholderSell12,674$35.75$453,095.50  
11/24/2021Ansbert GadickeMajor ShareholderSell60,808$36.29$2,206,722.32  
11/23/2021Michel DetheuxCEOSell14,500$36.08$523,160.00  
11/22/2021Ansbert GadickeMajor ShareholderSell35,333$37.52$1,325,694.16  
11/18/2021Joanne Jenkins LagerInsiderSell28,000$34.50$966,000.00  
11/3/2021Michel DetheuxCEOSell6,085$28.89$175,795.65  
11/1/2021Michel DetheuxCEOSell81$28.00$2,268.00  
10/21/2021Michel DetheuxCEOSell196$28.00$5,488.00  
10/19/2021Michel DetheuxCEOSell201$28.00$5,628.00  
10/18/2021Bioventures 2018 L.P. MpmMajor ShareholderSell6,167$27.14$167,372.38  
10/15/2021Bioventures 2018 L.P. MpmMajor ShareholderSell10,932$27.62$301,941.84  
10/15/2021Michel DetheuxCEOSell1,635$28.01$45,796.35  
10/13/2021Bioventures 2018 L.P. MpmMajor ShareholderSell20,929$27.13$567,803.77  
10/11/2021Bioventures 2018 L.P. MpmMajor ShareholderSell48,812$27.24$1,329,638.88  
10/7/2021Bioventures 2018 L.P. MpmMajor ShareholderSell1,149$27.00$31,023.00  
10/4/2021Bioventures 2018 L.P. MpmMajor ShareholderSell20,711$27.06$560,439.66  
9/30/2021Bioventures 2018 L.P. MpmMajor ShareholderSell2,292$27.00$61,884.00  
9/27/2021Bioventures 2018 L.P. MpmMajor ShareholderSell11,625$27.09$314,921.25  
9/24/2021Bioventures 2018 L.P. MpmMajor ShareholderSell4,913$27.81$136,630.53  
9/23/2021Michel DetheuxCEOSell5,322$28.16$149,867.52  
9/22/2021Bioventures 2018 L.P. MpmMajor ShareholderSell14,294$27.54$393,656.76  
9/20/2021Bioventures 2014 L.P. MpmMajor ShareholderSell24,303$27.49$668,089.47  
9/17/2021Bioventures 2014 L.P. MpmMajor ShareholderSell45,698$28.82$1,317,016.36  
9/15/2021Bioventures 2014 L.P. MpmMajor ShareholderSell24,104$27.80$670,091.20  
9/13/2021Ansbert GadickeMajor ShareholderSell35,785$27.64$989,097.40  
9/9/2021Ansbert GadickeMajor ShareholderSell38,028$28.97$1,101,671.16  
9/7/2021Ansbert GadickeMajor ShareholderSell50,996$29.18$1,488,063.28  
9/1/2021Michel DetheuxCEOSell8,684$28.30$245,757.20  
8/30/2021Michel DetheuxCEOSell2,322$28.01$65,039.22132,104  
8/27/2021Michel DetheuxCEOSell8,248$28.17$232,346.16  
8/25/2021Michel DetheuxCEOSell861$28.00$24,108.00  
8/23/2021Michel DetheuxCEOSell7,499$28.06$210,421.94141,438  
6/16/2021Matthew GallCFOBuy5,000$26.09$130,450.005,000  
6/14/2021Michel DetheuxCEOSell29,000$28.50$826,500.00152,874  
6/8/2021Yvonne McgrathVPSell7,927$20.00$158,540.007,927  
5/24/2021Yvonne McgrathVPSell7,927$21.92$173,759.847,927  
4/9/2021Bioventures 2014 L.P. MpmMajor ShareholderSell119$29.99$3,568.81  
4/7/2021Bioventures 2014 L.P. MpmMajor ShareholderSell5,783$32.55$188,236.65  
(Data available from 1/1/2013 forward)

iTeos Therapeutics (NASDAQ:ITOS) Insider Trade Frequently Asked Questions

Who is on iTeos Therapeutics's Insider Roster?

The list of insiders at iTeos Therapeutics includes Aaron I Davis, Ansbert Gadicke, Bioventures 2014 L.P. Mpm, Bioventures 2018 L.P. Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Matthew Gall, Michel Detheux, and Yvonne Mcgrath. Learn more on insiders at ITOS.

What percentage of iTeos Therapeutics stock is owned by insiders?

3.95% of iTeos Therapeutics stock is owned by insiders. Learn more on ITOS's insider holdings.

Which iTeos Therapeutics insiders have been buying company stock?

The following insiders have purchased iTeos Therapeutics stock in the last 24 months: Aaron I Davis ($968,400.00), and Matthew Gall ($130,450.00).

How much insider buying is happening at iTeos Therapeutics?

Insiders have purchased a total of 35,000 iTeos Therapeutics shares in the last 24 months for a total of $1,098,850.00 bought.

Which iTeos Therapeutics insiders have been selling company stock?

The following insiders have sold iTeos Therapeutics stock in the last 24 months: Aaron I Davis ($18,292,500.00), Ansbert Gadicke ($7,111,248.32), Bioventures 2014 L.P. Mpm ($2,847,002.49), Bioventures 2018 L.P. Mpm ($11,619,235.61), Boxer Capital, Llc ($20,275,835.25), David Hallal ($2,178,500.00), Detlev Biniszkiewicz ($181,650.00), Joanne Jenkins Lager ($2,126,180.00), Matthew Gall ($232,250.00), Michel Detheux ($5,652,120.56), and Yvonne Mcgrath ($699,899.84).

How much insider selling is happening at iTeos Therapeutics?

Insiders have sold a total of 2,354,546 iTeos Therapeutics shares in the last 24 months for a total of $71,216,422.07 sold.

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.